Indoco Remedies has formally completed the transfer of its ophthalmic business division to Sunways (India) Private Limited as a going concern on a slump sale basis, effective May 18, 2026. The company disclosed this development to the stock exchanges in continuation of its earlier intimation dated April 30, 2026, which had announced the approval and execution of the Agreement to Transfer Business (ATB).

Business Transfer Details

The transfer encompasses the company's Ophthalmic Division across a defined set of territories. All conditions precedent stipulated under the ATB have been fulfilled, enabling the completion of the transaction on the stated date. The following table summarises the key parameters of the transaction:

Territories Covered

The business transfer covers the ophthalmic division's operations across the following territories:

• India
• West Africa: Benin, Burkina Faso, Ivory Coast, Mali, Niger, Mauritania, Senegal
• Central Africa: Cameroon, Congo, Gabon
• East & Southern Africa: Kenya, Tanzania, Zambia, Zimbabwe, Botswana, Namibia

Regulatory Disclosure

The intimation regarding the completion of the business transfer was submitted to both the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited under Regulation 30. The disclosure was signed by Ramanathan Hariharan, Company Secretary & Head Legal of Indoco Remedies Limited, on May 18, 2026.

Indoco Remedies has secured the EU GMP (Good Manufacturing Practice) Certification from the Malta Medicines Authority, affirming that its facility meets the stringent Good Manufacturing Standards required under European Union regulatory frameworks. This certification is a formal recognition of the company's manufacturing quality and compliance capabilities.

EU GMP Certification: Key Details

The following table summarizes the key details of the certification:

Significance of the Certification

The EU GMP Certification issued by the Malta Medicines Authority is a widely recognized regulatory credential that validates a manufacturing facility's compliance with European Union standards for pharmaceutical production. Obtaining this certification demonstrates that Indoco Remedies' facility adheres to the quality, safety, and operational benchmarks mandated for pharmaceutical manufacturers seeking to operate within or supply to European markets.

This development represents a notable regulatory achievement for Indoco Remedies, reflecting the company's commitment to maintaining internationally recognized manufacturing quality standards.